Last Update: Nov 09, 2026
A Randomized, Participant and Investigator-blinded, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia
ClinicalTrials.gov Identifier:
Novartis Reference Number:CXEP527A12105
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This study is designed to assess the safety and tolerability of the effects of XEP527, with particular emphasis on disease status and its compatibility with the standard of care in patients with stable schizophrenia. This is a randomized, participant and investigator blinded, placebo-controlled, multicenter study in stable schizophrenic patients divided into three dosing cohorts. This study will include a screening period up to 28 days, an inpatient treatment period of 28 days of the study drug (XEP527 or placebo) and a follow-up period of 28 days

Schizophrenia
Phase1
Recruiting
36
Nov 04, 2026
Mar 06, 2028
All
18 Years - 65 Years (Adult, Older Adult)

Interventions

Drug

Placebo

Placebo
Drug

XEP527

Participants will receive XEP527

Eligibility Criteria

Key Inclusion Criteria:

* Signed informed consent must be obtained prior to participation in the study
* Participants 18 to 65 years of age, inclusive at screening
* Participant agrees to be hospitalized starting at Day -1 and for at least 28 days after randomization
* Participant has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria and confirmed by Mini International Neuropsychiatric Interview for Schizophrenia and Psychotic Disorder Studies (MINI), version 7.0.2. at screening
* Participant meets the following requirements per PANSS at screening and baseline: Total PANSS score ≤ 110, Score ≤ 4 (moderate) for item P1-P7, Score ≤ 4 (moderate) for G9
* Participant is treated with a single antipsychotic (typical and/or atypical) with a stable dose for at least 12 weeks prior to randomization. Participant must agree to maintain the treatment with standard of care antipsychotic for the duration of the study
* Participants who are treated with psychotropic medications other than antipsychotics need to be taking these medications as a stable dose for at least 12 weeks before randomization

Key Exclusion Criteria:

* Participant experienced worsening of schizophrenia within 3 months prior to randomization documented by symptom exacerbation and/or hospitalizations (hospitalization for social management and/or day hospital programs within this time are acceptable)
* Participant was treated with Clozapine, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) in the last 6 months prior to randomization
* Participant meets the DSM-5 criteria for another psychotic disorder
* Participant has a history of substance or alcohol use disorder, except nicotine or caffeine, within 1 year before screening, or current abuse as determined by urine drug screen or alcohol test
* Score "yes" on item 4 or item 5 of the Suicidal Ideation section of the C-SSRS, if this ideation occurred in the past 6 months, or "yes" on any item of the Suicidal Behavior section, except for the "Non-Suicidal Self-Injurious Behavior" (item also included in the Suicidal Behavior section), if this behavior occurred in the past 2 years.

Other protocol-defined inclusion/exclusion criteria may apply.

Pillar Clinical Research LLC

Recruiting

Bentonville,Arkansas,72712,United States

Eric Foster
Fayz A Hudefi

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals